{
  "events": [
    {
      "drug": "Application (NDA) | 2025-09-12 | PDUFA Date | BioCryst Pharmaceuticals, Inc. FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025\u2013 [View](https://www.benzinga.com/pressreleases/25/05/g45402162/biocryst-announces-fda-acceptance-of-nda-for-orladeyo-berotralstat-oral-granules-in-patients-with-) | [Get Alert](https://www.benzinga.com/profile/portfolio/?action=login&utm_source=calendars) |",
      "indication": "",
      "company": "\u25b2\u25bc | Price \u25b2\u25bc | % change \u25b2\u25bc | Name and Treatment \u25b2\u25bc | Status \u25b2\u25bc | Catalyst Date \u25b2\u25bc | Catalyst \u25b2\u25bc | Description \u25b2\u25bc | Get Alert |",
      "pdufa_date": "| BioCryst Pharmaceuticals, Inc. FDA grants Priority Review of application, with PDUFA target action date of September 12, 2025\u2013 [View](https://www.benzinga.com/pressreleases/25/05/g45402162/biocryst-announces-fda-acceptance-of-nda-for-orladeyo-berotralstat-oral-granules-in-patients-with-) | [Get Alert](https://www.benzinga.com/profile/portfolio/?action=login&utm_source=calendars) |",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "With FDA Nod For Saxenda](https://www.benzinga.com/news/health-care/25/08/47397079/teva-launches-generic-glp-1-weight-loss-drug-with-fda-nod-for-saxenda)",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "application, or NDA, supplemental NDA, Biologic License Application, or BLA, supplemental BLA, Premarket Approval Application, or Premarket Notification 510(k), etc",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "names or tickers, events, date-wise or based on a date range. They are designed to serve as a \u2018one-stop shop\u2019 for data needs of investors, both existing and potential, to capitalize on the opportunities these catalysts throw up or cut the losses from an adverse development.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "development, which usually takes about 10-15 years, on the promise of generating future returns.",
      "indication": "",
      "company": "and as a result generate revenues in the form of licensing revenues. So, it will be years of investment (time money and efforts) into drug development, which usually takes about 10-15 years, on the promise of generating future returns.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "development is perceived by the market as an incremental step in bringing the company closer to that distant goal of marketing a potential blockbuster drug that could fetch it billions in revenues. This explains the huge positive move in a stock when a company reports a positive clinical readout.",
      "indication": "",
      "company": "closer to that distant goal of marketing a potential blockbuster drug that could fetch it billions in revenues. This explains the huge positive move in a stock when a company reports a positive clinical readout.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "may have made in the investigational therapy could go down the drain. Quite appropriately, investors punish the stock by selling it in droves.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "| Close \u25b2\u25bc | \u00b1% | Avg. Vol \u25b2\u25bc | Buy Stock |",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "| Close \u25b2\u25bc | \u00b1% | Avg. Vol \u25b2\u25bc | Buy Stock |",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "User Fee Act date, in short, PDUFA date, refers to the date/period by which the FDA is mandated to give its verdict on the regulatory application filed by the sponsor company. The verdict can be an \u2018approved\u2019 decision, or a \u2018complete response letter\u2019 or a delay due to reasons specific to the company or extraneous to the company.",
      "indication": "",
      "company": "or extraneous to the company.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "to fund the review process.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "ingredients are being made etc.",
      "indication": "",
      "company": "",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "may roughly calculate a timeline based on the data of filing the regulatory application. If the company doesn\u2019t provide a timeline either, it is left to the investors to do the calculations.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    },
    {
      "drug": "",
      "indication": "",
      "company": "files for a regulatory application, the FDA takes up to 60 days to respond with an \u2018accepted for review\u2019 or \u2018refuse-to-file\u2019 decision.",
      "pdufa_date": "",
      "fda_date_no_pdufa": "",
      "source_url": "https://www.benzinga.com/fda-calendar/exact-dates"
    }
  ]
}